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Letter to the EditorSignal transducer and activator of
transcription 5B deficiency due to a
novel missense mutation in the
coiled-coil domainTo the Editor:
We report a 17-year-old boy who presented with growth
hormone (GH)-refractory growth failure (Fig 1, A), severe
eczema (Fig 1,B), and autoimmunity. Hewas born to consanguin-
eous parents at term with normal gestational weight (3.4 kg) and
length (51 cm). He initially presented with autoimmune thyroid-
itis at age 4 years, with symptoms of lethargy, poor growth, de-
layed bone age, and constipation (Fig 1, C), confirmed by high
titers of antithyroid peroxidase antibodies (>1000 IU/L; normal
range, <34 IU/L) and antithyroglobulin antibodies (680 IU/L;
normal range, <100 IU/L). He was treated with L-thyroxine (lev-
othyroxine), which led to some improvement in his weight and
growth. He also suffered from iron-deficiency anemia, which
was treated with iron (III) hydroxide polymaltose (Maltofer),
and ichthyosis from infancy, and developed atopic dermatitis at
the age of 7 years. At age 9 years, he lost his head-hair, eyebrows,
and eyelashes, and alopecia persisted despite treatment with ste-
roids (prednisolone) on several occasions; this also failed to
resolve his ongoing dermatitis. Three years later he was started
on a gluten-free diet after antigliadin antibodies were detected
in his blood; however, he had no anti–tissue transglutaminase an-
tibodies and did not meet the clinical criteria of celiac disease.
Furthermore, because there was no symptomatic improvement,
the gluten-free diet was stopped after 2 years. Meanwhile, he
maintained poor linear growth and delayed puberty. He had
normal concentrations of basal GH, but low levels of insulin-
like growth factor-1 (IGF-1) (Fig 1, D), IgA (see Table E1 in
this article’s Online Repository at www.jacionline.org), and
vitamin D. In 3 GH provocation tests he had peak GH levels of
less than 10 ng/mL (insulin, 7.35 ng/mL; glucagon, 3.17 ng/
mL; arginine, 4.88 ng/mL), which is a response characteristic
rather of GH deficiency than of GH insensitivity. However, ther-
apeutic trial with GH for 2 years did not improve growth velocity,
and IGF-1 remained below the normal limits throughout the
follow-up. Treatment with cyclosporine was started when he
was 14 years old and improved the eczema (Fig 1, B) and total al-
opecia, with some relapse of skin rash/thickened dry skin and al-
opecia after 1 year. Now he is in a stable condition on
cyclosporine therapy, with greatly improved skin status and prog-
ress into puberty, although he is still small for his age. Hypothy-
roidism is well compensated by L-thyroxine therapy, but he has
chronic recurring alopecia.
Assessment of his immunological status revealed a slight
reduction in naiveCD41TandB cells, a striking increase in class-
switched memory B cells, abundant activated HLA-DR1 T cells,
low levels of IgA and IgM, and increased levels of IgE (Table E1).
In an attempt to identify a presumed autosomal-recessive cause
of this striking phenotype, we undertook whole-exome 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy,Asthma& Immunology. This is an open access article under theCCBY license
(http://creativecommons.org/licenses/by/4.0/).sequencing and found a novel homozygous missense mutation
in the coiled-coil domain (CCD) of the gene STAT5B (signal
transducer and activator of transcription [STAT] 5B; Fig 2, A).
The nucleotide change c.452T>C, translating to p.L151P, was
confirmed by Sanger sequencing and was found to be heterozy-
gous in both parents and wild-type in the healthy sister (Fig 2,
B). The mutation is predicted to be deleterious by several predic-
tion programs (Fig 2, C). Indeed, our patient’s phenotype was
very compatible with that previously described for STAT5B defi-
ciency. STAT5 functions downstream of cytokines such as IL-2,
IL-4, IL-7, IL-9, IL-13, IL-15, IL-21, erythropoietin, thrombo-
poietin, and GH by translocating to the nucleus upon receptor
engagement and activating transcription of growth factors, tran-
scription factors, and other effector molecules. Even though
STAT5A and STAT5B share greater than 90% homology, they
have nonredundant as well as redundant functions.1 The GH re-
ceptor preferentially uses STAT5B to induce expression of IGF-
I, which promotes skeletal development and adipogenesis.2
STAT5B also regulates expression of the transcription factor
FOXP3 and the high-affinity IL-2 receptor subunit CD25, both
key molecules in the development and function of regulatory T
(Treg) cells.1 Thus, human STAT5B deficiency is characterized
by short stature due to GH insensitivity, and immune dysregula-
tion typically manifest as eczema, chronic diarrhea, recurrent in-
fections, and autoimmune diathesis.2 STAT5B-deficient patients
have normal levels of GH, but severely reduced serum levels of
IGF-I, and are refractory to GH treatment. Other characteristic
features are chronic lung diseases such as recurrent pneumonia,
lymphocytic interstitial pneumonitis, and/or lung fibrosis, as
well as moderate T-cell lymphopenia.2,3
Since the first mutation in STAT5B was reported in 2003, 9
more patients with autosomal-recessive2 and 13 individuals with
autosomal-dominant4,5 STAT5B deficiency were identified (Fig2,
A). Homozygous mutations were loss-of-function, with 5 frame-
shift or nonsense mutations and 2 missense mutations in the SH2
domain. Both of these missense mutations cause aberrant folding
of STAT5B, leading to protein aggregation, reduced expression
levels, and impaired transcriptional activity.6,7 AD STAT5B defi-
ciency with variable penetrance was caused by heterozygous
missense mutations in the CCD or the DNA-binding domain,
with intact expression of a mutant protein with dominant-
negative activity (Fig 2, A; see Table E2 in this article’s Online
Repository at www.jacionline.org).4,5 The CCD is important for
protein-protein interactions and nuclear import.8
To explore the pathogenicity of our patient’s p.L151P muta-
tion, we first checked for STAT5B protein expression by
immunoblotting, showing normal levels in patient EBV-B cells
compared with control (Fig 2, D). To test whether the mutant
STAT5B is functionally active, we stimulated PBMCs from the
patient and healthy controls with recombinant human IL-2 for
0 to 90minutes andmeasured STAT5 phosphorylation by flow cy-
tometry. Compared with 3 controls, the patient showed reduced
STAT5 phosphorylation (Fig 2, E). Because the antibody used
recognizes phosphorylated STAT5A and STAT5B, it is possible
that the remaining signal entirely reflects phosphorylated
STAT5A. A similar result was obtained using patient and control
EBV-B cells (data not shown). We next investigated Treg-cell
numbers and function, which have been shown to be reduced in1
Height (cm)
0 2 4 6 8 10 12 14 16 18 20
Age (years)
GH therapy 
(genotropin)
60
80
100
120
140
160
180
Age (years) Clinical Features
Birth Full term, Dry skin
4 Autoimmune Thyroiditis:
• Lethargy
• Poor growth
• Delayed bone age
• Constipation 
Iron deficiency anemia
Ichthyosis
7 Atopic dermatitis
9 Diffuse alopecia
12 celiac-like disease 
IgA and Vitamin D deficiency
15 GH-refractory growth failure
Delayed puberty
Severe eczema
PRE
POST
10 12 14 16
Age (years)
G
H
 (n
g/
m
L)
Normal range GH
Normal range IGF-1
10
IG
F-1 (ng/m
L)
700
600
500
400
300
200
100
0
9
8
7
6
5
4
3
2
1
0
Weight (kg)
Prednisolone
0 2 4 6 8 10 12 14 16 18 20
Age (years)
Gluten-
free diet
Cyclosporine 
started10
20
30
40
50
60
70
80
90
A
B C
D
FIG 1. Clinical characteristics. A, Height and weight of the patient from age 5 to 15 years. Periods of GH ther-
apy, gluten-free diet, and steroid treatment are indicated by arrows. B, Eczema and alopecia before (pre) and
after (post) cyclosporine treatment. C, Patient clinical features.D,GH (black line) and IGF-1 (red line) levels in
the patient over time. Shaded areas: normal ranges (black, GH; red, IGF-1).
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2 LETTER TO THE EDITORpatients with STAT5B deficiency.2 Compared with the travel con-
trol, the CD41CD25hiCD1272 Treg-cell population was reduced
by about half in the patient’s peripheral blood (Fig 2, F). Treg-cell
suppressive capacity was assessed with Treg cells from the patient
and a travel control (blood shipped for 36 hours) and an in-house
control (fresh blood) (see Fig E1,A, in this article’s Online Repos-
itory at www.jacionline.org). Patient’s Treg cells showedsignificantly reduced suppressive capacity compared with those
of the in-house control (P 5 .0021), but not the travel control
(Fig E1, B). Thus, unfortunately, no conclusion about Treg-cell
function can be drawn. T-cell proliferation to all mitogens
measured was in the normal range (Fig E1, C), albeit perhaps a
lower response in the patient was more pronounced for IL-2
(21,894 counts per minute patient vs 47,107 counts per minute
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FIG 2. Characterization of L151P. A, STAT5B schematic showing L151P in the CCD. Gray arrows: previously
reported pathogenic mutations. Each dot represents 1 individual with either autosomal-recessive (black) or
autosomal-dominant (blue) mutations. B, Sanger sequencing. C, L151P impact predictions. D, STAT5B
immunoblot, EBV-B cells (loading control: GAPDH). E, Phosflow analysis of pSTAT5. PBMCs stimulated
with 100 ng/mL IL-2 for 0 to 90minutes. Red line: patient; black line: average of 3 healthy controls. Histogram
plot: PBMCs gated on live CD31 lymphocytes. Gray area: fluorescence-minus-one (FMO) control; gray line:
unstimulated; black line: 15-minute stimulation. F, CD41CD25hiCD1272 Treg cells in patient and control.
Numbers indicate percentages of cells within the gate. GAPDH, Glyceraldehyde 3-phosphate
dehydrogenase.
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4 LETTER TO THE EDITORcontrol) than for othermitogens. The significance of this finding is
not clear, but could relate to a defect in STAT5B signaling down-
stream of the IL-2 receptor.
How a missense mutation in the CCD affects phosphorylation
of Y694 in the transcriptional activation domain is interesting to
consider. It has been shown for Stat3 that the a1 helix of the CCD,
through intramolecular interactions, is crucial for IL-6–induced
recruitment of Stat3 to the IL-6 receptor and subsequent Stat3
phosphorylation, nuclear translocation, and DNA binding.9
Because of high structural conservation between STAT proteins,
a similar mechanism might apply to the role of STAT5B’s CCD
in the recruitment of STAT5B to the IL-2 receptor and subsequent
phosphorylation. Interestingly, another STAT5B CCD mutation,
Q206R, also inhibits IL-2–induced STAT5B-Y694 phosphoryla-
tion.4 This heterozygous mutant has a dominant-interfering effect
on STAT5B transcriptional function and leads to a phenotype of
autoimmunity, lymphoproliferation, granulocytosis, and hypo-
gammaglobulinemia (patient 1), or multiple sclerosis, arthritis,
and recurrent infections (patient 2), but no GH insensitivity, de-
layed puberty, eczema, or pulmonary disease (see Table E2 in
this article’s Online Repository at www.jacionline.org).4 In
contrast, a further heterozygous STAT5B CCD mutant, Q177P,
is robustly phosphorylated, but exerts a dominant-negative effect
by abrogating STAT5B nuclear import.5 This mutation results in
GH-insensitive growth failure, delayed puberty, reduced IGF-1
levels, and severe eczema, as seen in our L151P patient and the
4 patients with nonsense and frameshift mutations in the
CCD.2,5 Both our patient and the Q177P index patient had normal
instead of elevated levels of prolactin, and raised IgE levels were
found in both Q177P and 1 R152X patient (Table E2).
In summary, this is the first report of a homozygous hypomor-
phic missense mutation in the STAT5BCCD leading to functional
defects and a phenotype of STAT5B deficiency. This included
GH-refractory growth failure, severe eczema, and autoimmune
disease but to date without pulmonary problems, severe in-
fections, or T-cell lymphopenia. It would have been ideal to treat
the GH insensitivity with IGF-1, but unfortunately, that was not
available for the patient. We observed a gratifying clinical
response of the atopic dermatitis to cyclosporine therapy,
coinciding with improved nutritional status, growth, and general
well-being. However, the long-term outlook remains guarded.
Alternative treatment strategies for immune dysregulation one
might consider if symptoms deteriorated include sirolimus
therapy or even stem cell transplantation.
For detailed methods, please see theMethods section in this ar-
ticle’s Online Repository at www.jacionline.org.We thank clinical and laboratory colleagues and the patients and their
families for their participation.
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METHODS
Study subjects
Patients and their relatives provided written informed consent to participate
in research protocols approved by the Newcastle and North Tyneside 1
Research Ethics Committee. Whole blood samples were obtained from these
individuals, and genomic DNA was isolated using the DNeasy or QIAamp
DNA mini kit (Qiagen, Manchester, UK).
PCR and sequencing analysis
Specific primerswere designed in Primer3webversion 4.0.0 (http://bioinfo.
ut.ee/primer3/). Primer sequences are available on request. Capillary
sequencing was performed according to standard methods. Sequences were
aligned with the consensus coding sequence (human genome assembly 38)
in nucleotide BLAST (http://blast.ncbi.nlm.nih.gov/blast/). ChromasLite
Version 2.1.1 was used for visualization of the sequences.
Whole-exome sequencing
Whole exome of the patient was captured using the Agilent SureSelect V5
kit and a library subsequently prepared for paired-end sequencing. This was
carried out on an Illumina NextSeq instrument, on a high-output flowcell by
OGT (Oxford Gene Technology, Begbroke, UK). Sequencing reads were
assessed for quality using the FastQC and MultiQC tools.E1,E2 Reads were
aligned to the hg19 assembly of the human reference genome, and prepared
for variant calling. Exomes were analyzed according to GATK best practi-
ces,E3 as follows: the raw alignment was realigned around indels, quality
scores recalibrated (Base Quality Score Recalibration [BQSR]), and dupli-
cates marked using the Picard suite. Genotyping was performed using a com-
bination of the HaplotypeCaller from GATK in the gVCF mode, and
JointCalling program leveraging a catalogue of exome samples from other pa-
tients with primary immunodeficiency. To avoid false-positive calls, Variant
Quality Score Recalibration (VQSR) was performed on the raw variant call-
sets for indels and single nucleotide polymorphisms. Downstream analysis
was carried out using the Web-based analytics application Ingenuity Variant
Analysis (Qiagen).
Cell lines
EBV-immortalized B-cell lines were generated from PBMCs after Ficoll-
purification from whole blood (EDTA). Cells were incubated with EBV-
containing medium for 1 hour initially, and then in the presence of 1 mg/mL
cyclosporine A for a further 24 hours at 378C, 5% CO2. Cells were then trans-
ferred to fresh 10%FCS/cyclosporineA–containing RPMI and incubated until
foci of immortalized cells appeared.
Immunoblotting
Cell lysates were prepared from patient and control EBV-B cells. Equal
amounts of lysate were separated by electrophoresis on a 4% to 12%
polyacrylamide gradient gel in 3-(N-morpholino)propanesulfonic acid buffer
(NuPAGE; Novex, Fisher Scientific, Loughborough, UK) and transferred to a
polyvinylidene fluoride or polyvinylidene difluoride membrane (Immobilon-
P; Millipore, Watford, UK). STAT5B was probed using rabbit-anti-human
STAT5B mAb (EPR16671, Abcam, Cambridge, UK) and anti-rabbit IgG,
horseradish peroxidase–linked secondary antibody (Cell Signalling Technol-
ogy [London, UK], 7074P2). Anti–glyceraldehyde 3-phosphate dehydroge-
nase antibody (Cell Signalling Technology, 5174S) was used as a loading
control.
Flow cytometry
Whole blood (EDTA) was rested for 2 hours at room temperature and then
stimulated for 0, 15, 30, and 90 minutes at 378C with 0.1 mg/mL recombinant
human IL-2 (Peprotech [London, UK], 200-02). Alternatively, EBV-B cells
were serum-starved for 1 hour and then stimulated with 0.5 mg/mL recom-
binant human IL-2. Whole blood cells were stained for the surface marker
CD3 and intracellularly for phosphorylated STAT5 (pSTAT5), EBV-B cells for
pSTAT5 only. Samples were acquired using a FACSCanto II cytometer (BD
Biosciences [BD], Wokingham, UK) and analyzed with FlowJo (Treestar,
Ashland, Ore). The following antibodies were used: Pacific Blue mouse anti-
human CD3 (clone UCHT1, BD Biosciences) and Alexa Fluor 647 mouse
anti-human STAT5 (pY694) (clone 47, BD Biosciences).
Lymphocyte proliferation
PBMCs were cultured for 3 days with the respective mitogens, and
proliferative responses were measured as counts per minute of tritiated
thymidine incorporated during cell division. Cultures were performed in
triplicate, with results expressed as the means of the triplicates. The
stimulatory index is calculated as stimulated over unstimulated (control)
counts.
Treg-cell suppression assay
CD41 T cells were enriched using RosetteSep (Stemcell Technologies,
Cambridge, UK). To isolate CD41CD252 effector T cells (Teff), CD25 mi-
crobeads and an LD column were used (both Miltenyi Biotec) on a fresh
healthy control sample. The Teff cells were labeled with Cell trace violet (In-
vitrogen, Thermo Fisher Scientific, Loughborough, UK) and stimulated with
anti-CD2/CD3/CD28-human Treg-cell inspector beads (Miltenyi Biotec,
Woking, UK) for 4 days. Treg cells from the patient, a travel control (36-
hour old blood samples), and an in-house control (fresh blood sample) were
purified via flow sorting (FACS Fusion, BD) gated on CD41CD25hiCD1272
cells. These cells were added at a ratio of 1:1 to the Teff population during the
stimulation period. Proliferating Teff cells were evaluated using a FACSCanto
flow cytometer (BD). Cultures were performed in sextuplicates.
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FIG E1. A, Treg-cell suppression assay. Dotted line: Teff alone. Solid line: Teff stimulated with Treg-cell
inspector beads. Shaded area: Teff stimulated with Treg-cell inspector beads in the presence of Treg cells.
Proliferation of Cell trace violet-labeled Teffs was measured as dilution of the dye with every cell division.
Inhibition of Teff proliferation by Treg cells is shown by reduced dye dilution. Results are shown for the pa-
tient, a travel control (both performedwith 36-hour-old blood), and an in-house control (fresh blood). B, Per-
centage of proliferating cells with means of 6 replicates given. Patient’s Treg cells showed significantly
reduced suppressive capacity compared with those of the in-house (**Kruskal-Wallis-Test: P 5 .0021) but
not those of the travel control. C, Lymphocyte proliferation, measured as counts per minute (cpm) of incor-
porated tritiated thymidine, was normal to all mitogens tested. ConA, Concanavalin A; n.s., nonsignificant;
PMA, phorbol myristate acetate; S.I., stimulation index.
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TABLE E1. Laboratory evaluation of STAT5BL151P patient
Parameter Patient
Reference range*
(11-14 y)
Neutrophils 2810 cells/mL 1500-8000 cells/mL
Lymphocytes 3170 cells/mL 1700-6900 cells/mL
CD31 2995 cells/mL 900-4500 cells/mL
CD41 2315 cells/mL 500-2400 cells/mL
CD81 633 cells/mL 300-1600 cells/mL
CD191 270 cells/mL 200-2100 cells/mL
CD272IgM1IgD1
(naive)
51% 75%-87%
CD271IgM1IgD1
(memory)
9% 5%-10%
CD271IgM2IgD2
(class switch memory)
30% 3%-10%
CD41/CD45RA1/CD271
(naive)
240 cells/mL (8%) 300-800 cells/mL
CD42/CD45RA1/CD271
(naive)
180 cells/mL (6%) 150-400 cells/mL
CD42/CD45RA1/CD272
(effector)
60 cells/mL (2%) <60 cells/mL
Activated T cells (HLA-
DR1)
56% <30%
NK cells
(CD161/CD561)
205 cells/mL (6%) 70-1200 cells/mL
IgA 0.1 g/L 0.14-1.23 g/L
IgM 0.43 g/L 0.48-1.68 g/L
IgG 10.1 g/L 4.24-10.51 g/L
IgE 491 IU/mL 0-200 IU/mL
Tetanus antibody 0.31 IU/mL 0.1-10 IU/mL
Hemophilus B antibody 0.2 mg/L 1-20 mg/L
Pneumococcal serotypes:
protective responses
8/12 serotypes
Measles IgG Detected
Varicella zoster IgG Detected
Toxoplasma IgG Detected
HIV screen Negative
Hepatitis screen Negative
IGF-1 62.5 ng/mL 143-693 ng/mL
TSH 4.72 mIU/mL 0.4-4 mIU/mL
Prolactin 95.4 mIU/ml 53-360 mIU/mL
NK, Natural killer.
*In-house reference range.
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TABLE E2. Comparative table of CCD mutations in STAT5B
Characteristic L151P (n 5 1) Q177P (n 5 2) Q206R (n 5 2) R152X (n 5 2) c.424_427del (n 5 2)
Mutation Homozygous missense Heterozygous missense Heterozygous missense Homozygous nonsense Homozygous indel, frameshift
(p.L142fsX161)
STAT5B protein expression Normal Normal Normal Absent Unknown (expected:
absent)
STAT5 phosphorylation Reduced upon IL-2
stimulation of PBMCs
Increased upon GH and IFN-g
stimulation of fibroblasts;
defective nuclear import of
STAT5B
Reduced upon IL-2, IL-7, or IL-15
stimulation of T-cell blasts
Reduced upon IL-2 stimulation of
PBMCs
Unknown
Treg cells Reduced numbers of
CD41CD25hiCD1272
Treg cells
Unknown Normal frequency of CD41FoxP31
Treg cells, diminished CD25
expression (1/1)
Reduced numbers of CD41CD25hi
Treg cells (1/1)
Unknown
Postnatal growth failure Yes Yes (2/2) No Yes (2/2) Yes (2/2)
Delayed puberty Yes Yes (2/2) No Yes (2/2) Yes (1/1)
Basal GH (ng/mL) [<10 ng/mL] Normal (0.6-1.2) Normal (1/1) (0.4) Unknown Normal (2/2) (6.6; P1) (1.8; P2) Normal (2/2) (1.7; P1) (1; P2)
Basal IGF-1 (ng/mL) [95-400] Reduced (46-126) Reduced (2/2) (56; P1) (58; P2) Unknown Not detectable (2/2) Reduced (2/2) (34; P1) (<25; P2)
IgE Raised Raised (2/2) Unknown Raised (1/1) Normal (2/2)
Prolactin Normal Normal (1/1) Unknown Raised (1/1) Raised (2/2)
Eczema Severe Severe (1/1) No Severe (2/2) Present (2/2)
Autoimmunity Autoimmune thyroiditis,
alopecia
No Immune thrombocytopenic purpura
(P1)
No (P1)
Autoimmune thyroiditis (P2)
No (P1)
Thrombocytopenic
purpura (P2)
Chronic pulmonary disease No Yes (1/1) No Yes (2/2) Yes (2/2)
Viral infections No Unknown EBV VZV (2/2) Unknown
Others Celiac-like disease
Iron-deficiency anemia
Vitamin D deficiency
Reduced IgA
Asthma Splenomegaly, lymphadenopathy,
necrotizing granulomas/
granulocytosis
Hypogammaglobulinemia (P1)
Multiple sclerosis, arthritis, recurrent
infections (P2)
Chronic diarrhea
Reference E5 E6 E7,E8 E9
P1, Patient 1; P2, patient 2; (1/1), 1 of 1 patient analyzed; (2/2), 2 of 2 patients analyzed. J
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